SCHEMBL9909173

SCHEMBL9909173

COc1cccc(F)c1-c1c(C)c(C)nc2ccc(C(=O)O)cc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR5A P47898 2/20 0.49
HTT P42858 3/20 0.46
LMNA P02545 1/20 0.46
MAPK1 P28482 1/20 0.46
RAB9A P51151 1/20 0.46
TDP1 Q9NUW8 2/20 0.44
RORC P51449 3/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA4 P22748 1/20 0.40
CA6 P23280 1/20 0.40
CA7 P43166 1/20 0.40
TPMT P51580 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
PTGFR P43088 3/20 0.39
TTR P02766 1/20 0.39
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9907615 0.89 HTR5A (0.59) HTR5AHTTLMNATDP1PTGFR
SCHEMBL9925377 0.89 HTR5A (0.44) HTR5AHTTKDM4EMEN1KMT2A
SCHEMBL9909191 0.88 ALDH1A1 (0.49) HTR5ALMNARAB9AKDM4EALDH1A1
SCHEMBL9909305 0.87 HTR5A (0.70) HTR5A
SCHEMBL9907657 0.86 HTR5A (0.56) HTR5AHTTLMNATDP1PTGFR
SCHEMBL9907631 0.84 HTR5A (0.51) HTR5AHTTLMNATDP1RORC
SCHEMBL15500566 0.83 HTR5A (0.40) HTR5ARAB9AKDM4EALDH1A1HPGD
SCHEMBL9909245 0.82 HTR5A (0.57) HTR5AHTTLMNAMAPK1RAB9A
SCHEMBL9907579 0.80 LMNA (0.54) HTR5AHTTLMNATDP1PTGFR
SCHEMBL9907608 0.79 HTR5A (0.72) HTR5AHTTRAB9ATDP1PTGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E HTR5A 1/4885HTT 970/4885LMNA 4287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.